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The prevalence of viral hepatitis type B in Poland in the 
second half of the 1990s was higher than in Western 
countries. During the period from 1997 to 1999 an 
increasing number of patients with hepatitis virus type 
B (HBV) infections were hospitalized in the Department 
of Infectious Diseases of the Medical University of Lublin. 
Both limited therapeutic options and limited efficacy 
with the use of interferon gamma led to the use of oral 
nucleoside analogues, including lamivudine (3TC), in the 
treatment of chronic hepatitis B. 
Lamivudine is 2 ‘-deoxy, 3 ‘-thiacytidine and is phos- 
phorylated intracellularly to its triphosphate derivative. 
Unlike other DNA viruses, HBV during its replicative path- 
way in hepatocytes has a reverse transcription process 
from RNA to DNA, and this reverse transcription appears 
to be the main level of lamivudine antiviral activity. Unfor- 
tunately lamivudine has little effect on the episomal path- 
way, which uses closed circular DNA and occurs outside 
the human genome. That might be one of the reasons 
why recurrences of HBV replication are observed after 
cessation of therapy. Reduced HBV susceptibility to 
lamivudine appears to be conferred also by mutation at 
codon 552 (M552V) in the YMDD motif of the catalytic 
domain of HBV polymerase.‘,2 
Clinical trials have shown that lamivudine sup- 
presses HBV DNA levels in serum or causes it to become 
undetectable. The rate of sustained normalization of ala- 
nine transaminase (ALT) levels was more than 60%.“-6 Lai 
and colleagues treated 358 Chinese patients with 
chronic hepatitis with lamivudine. The primary end 
point was a reduction of at least two points in the 
Knodell necroinflammatory score. They recommended 
a dose of 100 mg daily.T Multicenter studies have shown 
an efficacy response (necroinflammatory histologic 
improvement, ALT normalization, and HBV DNA 
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clearance) in hepatitis B e antigen (HBeAg)-negative 
patients that is similar to that observed in patients with 
detectable HBeAg.3,5 
This report presents the case of a woman with 
chronic viral hepatitis type B, who became pregnant 
while receiving lamivudine. 
CASE PRESENTATION 
A 34-year-old female was hospitalized at the Department 
of Infectious Diseases, Medical University of Lublin, with 
chronic viral hepatitis B. The diagnosis was based on the 
results of biochemical, serologic, and histopathologic 
examinations. Third generation enzyme-linked 
immunosorbent assays (ELISA) (Abbott Laboratories, 
Chicago, IL) were used to detect hepatitis B surface anti- 
gen (HBsAg), antibody to hepatitis B e antigen (HBeAb) 
and antibodies to hepatitis B core antigen (HBcAb), 
HBsAb, HBeAg, HBcAb-IgM in the patient’s serum. Anti- 
bodies to hepatitis A virus and hepatitis C virus were 
undetectable. 
The serum HBV DNA level, measured using the 
hybridization method, was 221.2 pg/mL. Total bilirubin 
level was 1.3 mg/dL, and protein level was 7.6 g/dL. 
Serum ALT concentration during the 6 months prior to 
hospitalization ranged from 335 UI/L to 640 UI/L. Hema- 
tologic examination was normal: hemoglobin concentra- 
tion (HGB) was 13.1 g/dL; red blood cell count (RBC), 
4.34 M/L; hematocrit (HCT), 31.7%; white cell count 
(WBC), 4.7 K/L (neutrophils, 59%; lymphocytes, 39%; 
eosinophils, 2%); and platelet count (PLT), 190 K/L. Anti- 
nuclear and antimitochondrial antibodies were unde- 
tectable. Liver biopsy was performed and histologic 
examination showed a high intensity of inflammation and 
moderate fibrosis (grade III, stage II) with positive histo- 
chemical reaction to HBsAg. 
On June 7, 1999, therapy was started with lamivu- 
dine (3TC, Glaxo Wellcome, Greenford, Middlesex, United 
Kingdom) 150 mg daily. After 1 month of lamivudine ther- 
apy normalization of the serum ALT level and a reduced 
serum HBV-DNA level (18.3 pg/mL) were observed. Three 
months after the beginning of therapy the serum level of 
ALT was still normal and HBV DNA was undetectable in 
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serum. On November 3,1999, after 5 months of the treat- 
ment, lamivudine was discontinued when the patient dis- 
closed that she was 6 weeks pregnant. Before the start of 
lamivudine therapy the patient was told to take a reli- 
able contraceptive and avoid pregnancy. In spite of this 
precaution the patient became pregnant. There were no 
abnormalities in the course of the pregnancy, and on June 
23,2000, in the 38th week of gestation she spontaneously 
delivered a healthy child. The newborn weighed 3450 g 
and had an Apgar score of 9. The examination performed 
by a pediatrician did not reveal any abnormalities. 
On October 23,2000,4 months after delivery, labo- 
ratory examinations revealed normal aminotransferase 
activity (ALT, 23 UI/L.) and HBV DNA was undetectable in 
the serum of both the patient and the child. Unfortu- 
nately, the patient did not consent to a control liver 
biopsy, so it was not possible to assess histopathology. 
DISCUSSION 
Safety data on the use of lamivudine during pregnancy in 
HBV-infected subjects are limited. No reports of the use 
of lamivudine during the first trimester of pregnancy 
were found. Most of the available data regarding the phar- 
macokinetics of lamivudine in pregnancy have been 
obtained in studies of HIV-infected mothers. According to 
the Guidelines for the Use of Antiretroviral Agents in HIV- 
infected Patients prepared by the National Institutes of 
Health (NIH) Panel to Define Principles of Therapy of 
HIV Infection, lamivudine should be given to pregnant 
women with zidovudine, after 10 to 12 weeks’ gesta- 
tion.8-‘2 Lamivudine concentrations are detectable in 
maternal serum, amniotic fluid, umbilical cord, and neona- 
tal serum, indicating that the drug diffuses freely across 
the pIacenta.r~r” Available data from neonates born to HIV- 
infected mothers treated with lamivudine did not show 
any adverse effects on the developing fetus.10‘12 How- 
ever, preclinical animal studies indicate that lamivudine 
use in pregnancy poses potential fetal risk, and it has 
been classified as an FDA pregnancy category C agent.” 
The patient in this case report took lamivudine 
throughout the first trimester of pregnancy with no 
apparent ill effects on the fetus. Although this is just one 
case, it suggests that lamivudine may be safe in pregnancy 
and should be studied further. This case may be taken 
into consideration in case of unintended pregnancy in 
women taking lamivudine either therapeutically or pro- 
phylactically. 
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